Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC-MS/MS

International Immunopharmacology

Volumn 28, Issue 1, 2015, Pages 513-520

  Willrich, Maria Alice V ^a   Murray, David L ^a   Barnidge, David R ^a   Ladwig, Paula M ^a   Snyder, Melissa R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Infliximab; Mass spectrometry; Monoclonal antibody therapeutics; Selective reaction monitoring

Indexed keywords

IMMUNOGLOBULIN G; INFLIXIMAB; TRYPSIN; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; PEPTIDE;

ARTICLE; CHEMOLUMINESCENCE; DIGESTION; ELECTROCHEMOLUMINESCENCE; HUMAN; ISOTOPE LABELING; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MONITORING; PRIORITY JOURNAL; SELECTIVE REACTION MONITORING; SIGNAL NOISE RATIO; TANDEM MASS SPECTROMETRY; BLOOD;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; CHROMATOGRAPHY, LIQUID; HUMANS; IMMUNOGLOBULIN G; INFLIXIMAB; PEPTIDES; TANDEM MASS SPECTROMETRY;

EID: 84937889819     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2015.07.007     Document Type: Article

References (33)

1. M.A. Willrich, D.L. Murray, and M.R. Snyder Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases Transl. Res. 165 2015 270 282
2. I. Ordas, D.R. Mould, B.G. Feagan, and W.J. Sandborn Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms Clin. Pharmacol. Ther. 91 2012 635 646
3. G.A. Doherty, R.A. Miksad, A.S. Cheifetz, and A.C. Moss Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease Inflamm. Bowel Dis. 18 2012 1608 1616
4. N. Wu, Y.C. Lee, N. Shah, and D.J. Harrison Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study Clin. Ther. 36 2014 1231 1241 (41 e1-3)
5. F. Baert, M. Noman, S. Vermeire, G. Van Assche, G. D'Haens, A. Carbonez, and et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease N. Engl. J. Med. 348 2003 601 608
6. J.F. Colombel, W.J. Sandborn, W. Reinisch, G.J. Mantzaris, A. Kornbluth, D. Rachmilewitz, and et al. Infliximab, azathioprine, or combination therapy for Crohn's disease N. Engl. J. Med. 362 2010 1383 1395
7. M. Jurgens, J.M. Mahachie John, I. Cleynen, F. Schnitzler, H. Fidder, W. van Moerkercke, and et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease Clin. Gastroenterol. Hepatol. 9 2011 421 427 e1
8. W. Afif, E.V. Loftus Jr., W.A. Faubion, S.V. Kane, D.H. Bruining, K.A. Hanson, and et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease Am. J. Gastroenterol. 105 2010 1133 1139
9. A. Alawadhi, K. Alawneh, and Z.A. Alzahrani The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what's in it for African and Middle Eastern rheumatologists Clin. Rheumatol. 31 2012 1281 1287
10. F. Baert, D. Drobne, A. Gils, N. Vande Casteele, S. Hauenstein, S. Singh, and et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy Clin. Gastroenterol. Hepatol. 13 2015 1118 1124
11. C. Steenholdt Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease Dan Med. J. 60 2013 B4616
12. N. Vande Casteele, V. Ballet, G. Van Assche, P. Rutgeerts, S. Vermeire, and A. Gils Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment Gut 61 2012 321 (author reply 2)
13. N. Vande Casteele, A. Gils, S. Singh, L. Ohrmund, S. Hauenstein, P. Rutgeerts, and et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient Am. J. Gastroenterol. 108 2013 962 971
14. L.J. Dekker, L. Zeneyedpour, E. Brouwer, M.M. van Duijn, P.A. Sillevis Smitt, and T.M. Luider An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regions Anal. Bioanal. Chem. 399 2011 1081 1091
15. C. Hagman, D. Ricke, S. Ewert, S. Bek, R. Falchetto, and F. Bitsch Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrometry Anal. Chem. 80 2008 1290 1296
16. O. Heudi, S. Barteau, D. Zimmer, J. Schmidt, K. Bill, N. Lehmann, and et al. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry Anal. Chem. 80 2008 4200 4207
17. H. Jiang, J. Zeng, C. Titsch, K. Voronin, B. Akinsanya, L. Luo, and et al. Fully validated LC-MS/MS assay for the simultaneous quantitation of coadministered therapeutic antibodies in cynomolgus monkey serum Anal. Chem. 85 2013 9859 9867
18. H. Li, R. Ortiz, L. Tran, M. Hall, C. Spahr, K. Walker, and et al. General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies Anal. Chem. 84 2012 1267 1273
19. B.K. Matuszewski, M.L. Constanzer, and C.M. Chavez-Eng Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS Anal. Chem. 75 2003 3019 3030
20. T.M. Annesley Ion suppression in mass spectrometry Clin. Chem. 49 2003 1041 1044
21. P.M. Ladwig, D.R. Barnidge, M.R. Snyder, J.A. Katzmann, and D.L. Murray Quantification of serum IgG subclasses by use of subclass-specific tryptic peptides and liquid chromatography-tandem mass spectrometry Clin. Chem. 60 2014 1080 1088
22. N. Vande Casteele, R. Khanna, B.G. Levesque, L. Stitt, G.Y. Zou, S. Singh, and et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease Gut 2014
23. G.M. Bradley, and M. Oliva-Hemker Infliximab for the treatment of pediatric ulcerative colitis Expert Rev. Gastroenterol. Hepatol. 6 2012 659 665
24. W. Reinisch, W.J. Sandborn, P. Rutgeerts, B.G. Feagan, D. Rachmilewitz, S.B. Hanauer, and et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies Inflamm. Bowel Dis. 18 2012 201 211
25. E.A. Maser, R. Villela, M.S. Silverberg, and G.R. Greenberg Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease Clin. Gastroenterol. Hepatol. 4 2006 1248 1254
26. O. Ben-Bassat, A. Romanova, A. Iacono, S.P. Irwin, and G.R. Greenberg Tu1150 association of serum infliximab and antibodies to infliximab to long-term clinical outcome and mucosal healing in Crohn's disease Gastroenterology 144 2013 S-775
27. S.L. Wang, L. Ohrmund, S. Hauenstein, J. Salbato, R. Reddy, P. Monk, and et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum J. Immunol. Methods 382 2012 177 188
28. C. Plasencia, D. Pascual-Salcedo, P. Alcocer, M.G. Bonilla, A. Villalba, D. Peiteado, and et al. The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab Ann. Rheum. Dis. 72 2013 1888 1890
29. K.S. Nanda, A.S. Cheifetz, and A.C. Moss Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis Am. J. Gastroenterol. 108 2013 40 47 (quiz 8)
30. H. Imaeda, S. Bamba, K. Takahashi, T. Fujimoto, H. Ban, T. Tsujikawa, and et al. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment J. Gastroenterol. 49 2014 647 682
31. W. Wang, E.Q. Wang, and J.P. Balthasar Monoclonal antibody pharmacokinetics and pharmacodynamics Clin. Pharmacol. Ther. 84 2008 548 558
32. B. Kuang, L. King, and H.F. Wang Therapeutic monoclonal antibody concentration monitoring: free or total? Bioanalysis 2 2010 1125 1140
33. P.A. van Schouwenburg, T. Rispens, and G.J. Wolbink Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis Nat. Rev. Rheumatol. 9 2013 164 172